Search research articles
Contact Us
Filters
Showing results (421-430 of 456) with videos related to
Page
of 46
Sort By:
The Lancet. Oncology
|
April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.
Annals of Surgical Oncology
|
April 14, 2021
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
Carol J Swallow, Dirk C Strauss, Sylvie Bonvalot, et al.
The New England Journal of Medicine
|
September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
Rachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
NEJM Evidence
|
September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma
Paolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.
Nature Communications
|
January 3, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Paolo A Ascierto, Milena Casula, Jenny Bulgarelli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
The Lancet. Oncology
|
June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
Brigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Page
of 46
Search research articles
Search
Showing results (421-430 of 456) with videos related to
Sort By:
Page
of 46
The Lancet. Oncology
|
April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.
Annals of Surgical Oncology
|
April 14, 2021
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
Carol J Swallow, Dirk C Strauss, Sylvie Bonvalot, et al.
The New England Journal of Medicine
|
September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
Rachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
NEJM Evidence
|
September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma
Paolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.
Nature Communications
|
January 3, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Paolo A Ascierto, Milena Casula, Jenny Bulgarelli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
The Lancet. Oncology
|
June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
Brigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Page
of 46